Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04939792 · ClinicalTrials.gov registry record · Early Phase 1

Optimization of Blood Levels of 25(OH)-Vitamin D in African Americans

A Early Phase 1 study of Vitamin D Deficiency, sponsored by Louisiana State University Health Sciences Center Shreveport.

Completed
Registry status
Early Phase 1
Development phase
165
Enrollment target
1
Study location

NCT04939792 is a Early Phase 1 study of Vitamin D Deficiency that has completed, run by Louisiana State University Health Sciences Center Shreveport. The registered enrollment target is 165 participants, below the 272-participant average among 48 other Vitamin D Deficiency trials with a reported enrollment target (39% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04939792, a Early Phase 1 study of Vitamin D Deficiency, has completed, sponsored by Louisiana State University Health Sciences Center Shreveport.

COMPLETED
Registry status
Early Phase 1
Development phase
165 participants
Enrollment target
1
Study location

Study Summary

Two-thirds of the US population, particularly African Americans (AA), is at risk for inadequate or deficient 25-hydroxy-vitamin D (25(OH)VD). Epidemiological studies demonstrate an association between better health outcomes and higher blood levels of 25(OH)VD . Randomized controlled clinical trials have shown that, while supraphysiological high doses of VD are needed to achieve adequate blood levels of 25(OH)VD, not all subjects respond to them. Recent studies have also questioned the therapeutic effects of high-dose VD supplementation. Severe VD deficiency has been associated independently with the future risk of mild cognitive impairment (MCI) and dementia. A reduction in GSH and an increase in the oxidative stress levels of serum, erythrocytes, and circulating lymphocytes has been observed in MCI and Alzheimer disease, findings similar to those in VD deficient persons. Scholarly reviews conclude that excess oxidative stress is one of the major risk factors for AD and support a potential therapeutic role for L-cysteine (LC, a GSH precursor) and vitamin D (VD) supplementation in the treatment of Alzheimer disease symptoms. This application presents the investigators' design for a randomized, double-blind, placebo-controlled clinical trial to test the hypothesis that supplementation with VD in combination with L-cysteine (LC) is more successful at optimizing the statuses of 25(OH)VD \[biological signatures\] and simultaneously decreasing TNF-α, IR \[functional or clinical outcomes\], and oxidative stress, suggesting a better therapeutic approach compared with supplementation with VD alone in AA subjects.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Vitamin D
  • DRUG Vitamin D + L-cysteine
  • DRUG L-cysteine

Study Locations (1)

Louisiana

  • Louisiana State University Health Shreveport - Shreveport

Trial Details

FieldValue
Enrollment Target 165 participants
Start Date 2020-11-06
Est. Completion 2022-10-31
Phase Early Phase 1

What the Registry Record Tells You About NCT04939792

The ClinicalTrials.gov registry entry for NCT04939792 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 165 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 272-participant average among 48 other Vitamin D Deficiency trials with a reported enrollment target (39% lower). The listed sponsor is Louisiana State University Health Sciences Center Shreveport, which has 40 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Vitamin D Deficiency appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.

NCT04939792 reports 1 study location spanning 1 distinct geographic area - top geographies include Louisiana.

Frequently Asked Questions

What is clinical trial NCT04939792 about?

NCT04939792 is a clinical study titled "Optimization of Blood Levels of 25(OH)-Vitamin D in African Americans". Two-thirds of the US population, particularly African Americans (AA), is at risk for inadequate or deficient 25-hydroxy-vitamin D (25(OH)VD). Epidemiological studies demonstrate an association between better health outcomes and higher blood levels of 25(OH)VD . Randomized controlled clinical trials ...

What is the current status of trial NCT04939792?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 165 participants. The study started on 2020-11-06. Estimated completion is 2022-10-31.

What conditions does trial NCT04939792 study?

This clinical trial studies the following conditions: Vitamin D Deficiency.

What interventions are being tested in trial NCT04939792?

The interventions under investigation include: Placebo (DRUG), Vitamin D (DRUG), Vitamin D + L-cysteine (DRUG), L-cysteine (DRUG).

Who is sponsoring clinical trial NCT04939792?

This trial is sponsored by Louisiana State University Health Sciences Center Shreveport, which has 40 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04939792 being conducted?

This trial has 1 study location across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Vitamin D Deficiency

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.